MENTIS Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • MENTIS's estimated annual revenue is currently $11M per year.(i)
  • MENTIS's estimated revenue per employee is $145,000

Employee Data

  • MENTIS has 76 Employees.(i)

MENTIS's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.2M20225%N/AN/A
#2
$42.9M26944%N/AN/A
#3
$900.3M443511%N/AN/A
#4
$1320M19968%$445MN/A
#5
$603.8M291216%$565MN/A
#6
$17.4M1204%N/AN/A
#7
$107.1M5914%$95.6MN/A
#8
$724.1M349232%$409MN/A
#9
$106.6M58822%N/AN/A
#10
$19.4M133-3%$46.6MN/A
Add Company

What Is MENTIS?

keywords:N/A

N/A

Total Funding

76

Number of Employees

$11M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

MENTIS News

2022-04-13 - Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers

Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology,...

2022-04-13 - BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism, and Diagnostics.

BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue...

2022-04-06 - Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism

Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.6M7641%N/A
#2
$12.5M761%N/A
#3
$11M7631%$46.5M
#4
$9.9M76N/AN/A
#5
$20.5M76N/AN/A